CTLA4 and neoplasm: Immunotherapies deploying inhibitors of programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) are important in the treatment of gastric cancer patients, especially in advanced cases, but unfortunately they have poor efficacy for this tumor type [6–8].